Results of liquid biopsy studies by next generation sequencing in patients with advanced stage non-small cell lung cancer: Single center experience from Turkey

1Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. Pathology and Genetics of Tumors of the Lung, Pleura, Thymus, and Heart, 4th ed. Lyon, France: International Agency for Research on Cancer Press; 2015. Travis WD Brambilla E Burke AP Marx A Nicholson AG Pathology and Genetics of Tumors of the Lung, Pleura, Thymus, and Heart, 4th ed Lyon, France International Agency for Research on Cancer Press 2015Search in Google Scholar

2Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: Guideline from the college of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med. 2018; 142(3): 321-346. Lindeman NI Cagle PT Aisner DL Arcila ME Beasley MB Bernicker EH et al Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: Guideline from the college of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology Arch Pathol Lab Med 2018 1423 321 34610.5858/arpa.2017-0388-CPSearch in Google Scholar

3Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014; 20(5): 548-554. Newman AM Bratman SV To J Wynne JF Eclov NC Modlin LA et al An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage Nat Med 2014 205 548 55410.1038/nm.3519Search in Google Scholar

4Thompson JC, Yee SS, Troxel AB, Savitch SL, Fan R, Balli D, et al. Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next-generation sequencing of cell-free circulating tumor DNA. Clin Cancer Res. 2016; 22(23): 5772-5782. Thompson JC Yee SS Troxel AB Savitch SL Fan R Balli D et al Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next-generation sequencing of cell-free circulating tumor DNA Clin Cancer Res 2016 2223 5772 578210.1158/1078-0432.CCR-16-1231Search in Google Scholar

5Schwaederlé MC, Patel SP, Husain H, Ikeda M, Lanman RB, Banks KC, et al. Utility of genomic assessment of blood-derived circulating tumor DNA (ctDNA) in patients with advanced lung adenocarcinoma. Clin Cancer Res. 2017; 23(17): 5101-5111. Schwaederlé MC Patel SP Husain H Ikeda M Lanman RB Banks KC et al Utility of genomic assessment of blood-derived circulating tumor DNA (ctDNA) in patients with advanced lung adenocarcinoma Clin Cancer Res 2017 2317 5101 511110.1158/1078-0432.CCR-16-2497Search in Google Scholar

6Sawada K, Kotani D, Bando H. The clinical landscape of circulating tumor DNA in gastrointerstinal malignancies. 2018; 8: 263. doi: 10.3389/fonc.2018.00263. eCol lection 2018. Sawada K Kotani D Bando H The clinical landscape of circulating tumor DNA in gastrointerstinal malignancies 2018 8 263 10.3389/fonc.2018.00263 eCol lection 2018Open DOISearch in Google Scholar

7Esposito AR, Pasquale R, Fenizia F, Rachiglio AM, Roma C, Bergantino F, et al. The role of circulating free DNA in the management of NSCLC. Expert Rev Anticancer Ther. 2019; 19(1): 19-28. Esposito AR Pasquale R Fenizia F Rachiglio AM Roma C Bergantino F et al The role of circulating free DNA in the management of NSCLC Expert Rev Anticancer Ther 2019 191 19 2810.1080/14737140.2019.1548938Search in Google Scholar

8Uchida J, Kato K, Kukita Y, Kumagai T, Nishino K, Daga H, et al. Diagnostic accuracy of non invasive genotyping of EGFR in lung cancer patients by deep sequencing of plasma cell-free DNA. Clin Chem. 2015; 61(9): 1191-1196. Uchida J Kato K Kukita Y Kumagai T Nishino K Daga H et al Diagnostic accuracy of non invasive genotyping of EGFR in lung cancer patients by deep sequencing of plasma cell-free DNA Clin Chem 2015 619 1191 119610.1373/clinchem.2015.241414Search in Google Scholar

9Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-celllung cancer. N Engl J Med. 2005; 353(2): 123-132. Shepherd FA Rodrigues PereiraJ Ciuleanu T Tan EH Hirsh V Thongprasert S et al Erlotinib in previously treated non-small-celllung cancer N Engl J Med 2005 3532 123 13210.1056/NEJMoa050753Search in Google Scholar

10Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomized, placebo controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2004; 366(9496): 1527-1537. Thatcher N Chang A Parikh P Rodrigues PereiraJ Ciuleanu T von PawelJ et al Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomized, placebo controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 2004 3669496 1527 153710.1016/S0140-6736(05)67625-8Search in Google Scholar

11Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13(3): 239-246. Rosell R Carcereny E Gervais R Vergnenegre A Massuti B Felip E et al Erlotinib versus standard chemotherapy as first line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial Lancet Oncol 2012 133 239 24610.1016/S1470-2045(11)70393-XSearch in Google Scholar

12Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in nonsmall-cell lung cancer. N Engl J Med. 2010; 363(18): 1693-1703. Kwak EL Bang YJ Camidge DR Shaw AT Solomon B Maki RG et al Anaplastic lymphoma kinase inhibition in nonsmall-cell lung cancer N Engl J Med 2010 36318 1693 170310.1056/NEJMoa1006448Search in Google Scholar

13Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, et al. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: An open-label, phase 2 trial. Lancet Oncol. 2017; 18(10): 1307-1316. Planchard D Smit EF Groen HJM Mazieres J Besse B Helland Å et al Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: An open-label, phase 2 trial Lancet Oncol 2017 1810 1307 131610.1016/S1470-2045(17)30679-4Search in Google Scholar

14Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, et al. Non-small cell lung cancer, version 6.2015. J Natl Compr Canc Netw. 2015; 13(5): 515-524. Ettinger DS Wood DE Akerley W Bazhenova LA Borghaei H Camidge DR et al Non-small cell lung cancer, version 6.2015 J Natl Compr Canc Netw 2015 135 515 52410.6004/jnccn.2015.007125964637Search in Google Scholar

15Mok T, Wu YL, Lee JS, Yu CJ, Sriuranpong V, Sandoval-Tan J, et al. Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib. Clin Cancer Res. 2015; 21(14): 3196-3203. Mok T Wu YL Lee JS Yu CJ Sriuranpong V Sandoval-Tan J et al Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib Clin Cancer Res 2015 2114 3196 320310.1158/1078-0432.CCR-14-259425829397Search in Google Scholar

16Douillard JY, Ostoros G, Cobo M, Ciuleanu T, Cole R, McWalter G, et al. Gefitinib treatment in EGFR mutated caucasian NSCLC: Circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol. 2014; 9(9): 1345-1353. Douillard JY Ostoros G Cobo M Ciuleanu T Cole R McWalter G et al Gefitinib treatment in EGFR mutated caucasian NSCLC: Circulating-free tumor DNA as a surrogate for determination of EGFR status J Thorac Oncol 2014 99 1345 135310.1097/JTO.0000000000000263422458925122430Search in Google Scholar

17Reck M, Hagiwara K, Han B, Tjulandin S, Grohé C, Yokoi T, et al. ctDNA determination of EGFR mutation status in European and Japanese patients with advanced NSCLC: The ASSESS study. J Thorac Oncol. 2016; 11(10): 1682-1689. Reck M Hagiwara K Han B Tjulandin S Grohé C Yokoi T et al ctDNA determination of EGFR mutation status in European and Japanese patients with advanced NSCLC: The ASSESS study J Thorac Oncol 2016 1110 1682 168910.1016/j.jtho.2016.05.03627468938Search in Google Scholar

18Dearden S, Stevens J, Wu YL, Blowers D. Mutation incidence and coincidence in non small-cell lung cancer: Meta-analyses by ethnicity and histology (mutMap). Ann Oncol. 2013; 24(9): 2371-2376. Dearden S Stevens J Wu YL Blowers D Mutation incidence and coincidence in non small-cell lung cancer: Meta-analyses by ethnicity and histology (mutMap) Ann Oncol 2013 249 2371 237610.1093/annonc/mdt205375533123723294Search in Google Scholar

19Zhang X-C, Wang J, Shao G-G, Wang Q, Qu X, Wang B, et al. Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients. Nat Commun. 2019; 10(1): 1772. Zhang X-C Wang J Shao G-G Wang Q Qu X Wang B et al Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients Nat Commun 2019 101 177210.1038/s41467-019-09762-1646789330992440Search in Google Scholar

20Song Z, Wang H, Yu Z, Lu P, Xu C, Chen G, et al. De novo MET amplification in Chinese patients with non-small-cell lung cancer and treatment efficacy with crizotinib: A multicenter retrospective study. Clin Lung Cancer. 2018; 20(2)): e 171-e176. Song Z Wang H Yu Z Lu P Xu C Chen G et al De novo MET amplification in Chinese patients with non-small-cell lung cancer and treatment efficacy with crizotinib: A multicenter retrospective study Clin Lung Cancer 2018 202 e171 e17610.1016/j.cllc.2018.11.00730554986Search in Google Scholar

21Asao T, Takahashi F, Takahashi K. Resistance to molecularly targeted therapy in non-small-cell lung cancer. Respir Investig. 2019; 57(1): 20-26. doi: 10.1016/j.resinv. 2018.09.001. Epub 2018 Oct 4. Asao T Takahashi F Takahashi K Resistance to molecularly targeted therapy in non-small-cell lung cancer Respir Investig 2019 571 20 26 10.1016/j.resinv 2018.09.001. Epub 2018 Oct 4Open DOISearch in Google Scholar

22Konduri K, Gallant JN, Chae YK, Giles FJ, Gitlitz BJ, Gowen K, et al. EGFR fusions as novel therapeutic targets in lung cancer. Cancer Discov. 2016; 6(6): 601-611. Konduri K Gallant JN Chae YK Giles FJ Gitlitz BJ Gowen K et al EGFR fusions as novel therapeutic targets in lung cancer Cancer Discov 2016 66 601 61110.1158/2159-8290.CD-16-0075489390727102076Search in Google Scholar

23Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017; 376(7): 629-640. Mok TS Wu YL Ahn MJ Garassino MC Kim HR Ramalingam SS et al Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer N Engl J Med 2017 3767 629 64010.1056/NEJMoa1612674676202727959700Search in Google Scholar

24Rolfo C, Giovannetti E, Hong DS, Bivona T, Raez LE, Bronte G, et al. Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. Cancer Treatment Rev. 2014; 40(8): 990-1004. Rolfo C Giovannetti E Hong DS Bivona T Raez LE Bronte G et al Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors Cancer Treatment Rev 2014 408 990 100410.1016/j.ctrv.2014.05.00924953979Search in Google Scholar

25Linda K, Mikael J, Kjell G, Jonas N. Liquid biopsies in lung cancer — time to implement research technologies in routine care? Ann Transl Med. 2017; 5(13): 278. Linda K Mikael J Kjell G Jonas N Liquid biopsies in lung cancer — time to implement research technologies in routine care? Ann Transl Med 2017 513 27810.21037/atm.2017.04.12551580428758104Search in Google Scholar